MIDAZOLAM KALCEKS 5 MGML

国: イスラエル

言語: 英語

ソース: Ministry of Health

即購入

ダウンロード 製品の特徴 (SPC)
16-03-2023

有効成分:

MIDAZOLAM

から入手可能:

A.L. MEDI-MARKET LTD.

ATCコード:

N05CD08

医薬品形態:

SOLUTION FOR INJECTION / INFUSION

構図:

MIDAZOLAM 5 MG / 1 ML

投与経路:

I.M, I.V

処方タイプ:

Required

製:

HBM PHARMA S.R.O., SLOVAKIA

治療領域:

MIDAZOLAM

適応症:

Midazolam Kalceks is a short-acting sleep-inducing drug that is indicated:In adults•CONSCIOUS SEDATION before and during diagnostic or therapeutic procedures with or without local anaesthesia•ANAESTHESIA- Premedication before induction of anaesthesia- Induction of anaesthesia- As a sedative component in combined anaesthesia•SEDATION IN INTENSIVE CARE UNITSIn children•CONSCIOUS SEDATION before and during diagnostic or therapeutic procedures with or without local anaesthesia•ANAESTHESIA- Premedication before induction of anaesthesia•SEDATION IN INTENSIVE CARE UNITS

承認日:

2020-12-15

製品の特徴

                                DOCTOR LEAFLET
1
NAME OF THE MEDICINAL PRODUCT
Midazolam Kalceks 1 mg/ml
Midazolam Kalceks 5 mg/ml
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Midazolam Kalceks
_1 MG/ML _
1 ml of solution contains 1 mg of midazolam.
One ampoule with 5 ml of solution contains 5 mg of midazolam.
Midazolam Kalceks
_5 MG/ML _
1 ml of solution contains 5 mg of midazolam.
One ampoule with 1 ml of solution contains 5 mg of midazolam.
One ampoule with 3 ml of solution contains 15 mg of midazolam.
One ampoule with 10 ml of solution contains 50 mg of midazolam.
Excipient with a known effect
Midazolam Kalceks
_1 MG/ML _
Each ml of solution contains 3.50 mg sodium.
Midazolam Kalceks
_5 MG/ML _
Each ml of solution contains 3.15 mg sodium.
For a full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Solution for injection/infusion.
Clear, colourless solution.
pH 2.9-3.7.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Midazolam is a short-acting sleep-inducing drug that is indicated:
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS
•
Concomitant use of benzodiazepines and opioids may result in profound
sedation, respiratory depression, coma, and death (see section 4.5).
•
Reserve concomitant prescribing of these drugs for use in patients for
whom alternative treatment options are inadequate.
•
Limit dosages and durations to the minimum required.
•
Follow patients for signs and symptoms of respiratory depression and
sedation.
IN ADULTS
•
CONSCIOUS SEDATION
before and during diagnostic or therapeutic procedures with or
without local anaesthesia
•
ANAESTHESIA
-
Premedication before induction of anaesthesia
-
Induction of anaesthesia
-
As a sedative component in combined anaesthesia
•
SEDATION IN INTENSIVE CARE UNITS
IN CHILDREN
•
CONSCIOUS SEDATION before and during diagnostic or therapeutic
procedures with or
without local anaesthesia
•
ANAESTHESIA
-
Premedication before induction of anaesthesia
•
SEDATION IN INTENSIVE CARE UNITS
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
STANDARD DOSAGE
Midazolam is a potent sedat
                                
                                完全なドキュメントを読む
                                
                            

この製品に関連するアラートを検索

ドキュメントの履歴を表示する